ReviewFrontiers in oncology2026
Exosome crown proteins are promising markers for liquid biopsy of breast cancer.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) remains the most common malignant disease in women. However, currently used instrumental and laboratory (CA15-3, CA125, etc.) diagnostic methods demonstrate insufficient sensitivity and specificity for early and reliable detection of BC. In this regard, great expectations are associated with the liquid biopsy method based on the identification of tumor cells or their components, including tumor-derived exosomes. The purpose of this study is to analyze current data on exosome proteins that can be used for diagnostics using liquid biopsy. This review discusses the role of exosomal crown proteins in the spread of BC and assesses their potential as diagnostic markers. The undoubted advantages of using exosomal crown proteins as tumor markers compared to other components of the tumor secretome are the simplicity and reproducibility of their analysis by flow cytometry, as well as, unlike microRNA, tissue specificity. In contrast to prior reviews that primarily catalogue extracellular vesicle cargo, we specifically assess surface-accessible proteins that combine biological relevance with analytical feasibility. This approach bridges mechanistic EV biology with the practical design of clinically translatable diagnostic assays. Standardization of protocols for exosome isolation, antibody validation, and signal amplification will be critical to the successful implementation of this approach into routine clinical practice. Integration of exosomal coronary protein profiling into modern oncology workflows may open new opportunities for early detection, long-term surveillance, and precision treatment of BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.